Most patients with advanced colorectal cancer treated with the drug panitumumab (Vectibix) develop resistance to the treatment, and a new study suggests why. Even before patients begin the treatment, a small percentage of their tumor cells may harbor genetic mutations that make the tumors resistant to the drug, researchers reported in Nature on June 13.